NZ Rheumatology Research Review Issue 49

In this issue:
  -  Long-term ustekinumab and TNF inhibitors in PsA
  -  Survival in RA-associated ILD
  -  Deucravacitinib for SLE
  -  Outcome score for SpA-related uveitis
  -  Methotrexate ± leflunomide in PsA
  -  ILD in biologic/targeted synthetic DMARD-treated RA
  -  Withholding methotrexate for 1 vs. 2 weeks for influenza vaccination
  -  COVID-19 outcomes among systemic rheumatic diseases
  -  Breakthrough SARS-COV-2 during rituximab for rheumatic/ musculoskeletal diseases
  -  Leflunomide for managing large-vessel vasculitis

Please login below to download this issue (PDF)

Subscribe